Crinetics Pharmaceuticals Announces April 2025 Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Core Points - Crinetics Pharmaceuticals granted stock options and restricted stock units (RSUs) to 26 new non-executive employees as part of its 2021 Employment Inducement Incentive Award Plan [1][2] - The stock options total 124,950 shares with an exercise price of $26.85 per share, equal to the closing price on April 10, 2025 [2] - The RSUs granted amount to 84,725 shares, with both stock options and RSUs vesting over four years [2] Company Overview - Crinetics Pharmaceuticals is a clinical stage pharmaceutical company focused on developing novel therapeutics for endocrine diseases and related tumors [3] - The lead candidate, paltusotine, is an investigational oral selective somatostatin receptor type 2 (SST2) nonpeptide agonist for acromegaly and carcinoid syndrome [3] - The company is also developing atumelnant, an oral ACTH antagonist for congenital adrenal hyperplasia and Cushing's disease, along with other drug candidates targeting various endocrine conditions [3]